New hope for Hard-to-Treat skin cancer: PTX-100 enters phase 2 trial

NCT ID NCT06854653

Recruiting now Disease control Sponsor: Prescient Therapeutics, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a drug called PTX-100 in 115 adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants receive PTX-100 by IV infusion over several cycles. The goal is to see if the drug can shrink or eliminate tumors and to check its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PTX-100 (a drug that blocks a protein involved in cancer cell growth)
What this could lead to: If it works, this could provide a new treatment option for people with cutaneous T-cell lymphoma who have not responded to other therapies.
What could go wrong: This is an early-phase trial with only 115 participants, so results may not apply to everyone. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides non-Hodgkin lymphoma primary cutaneous T-cell non-Hodgkin lymphoma Recurrence Sezary syndrome T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTCL

Contacts and locations

Locations

CHU de Bordeaux - Hopital Saint André
NOT_YET_RECRUITING

Bordeaux, Bordeaux, 33000, France
City of Hope Comprehensive Cancer Cente
RECRUITING

Duarte, California, 91010, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 022155450, United States
Epworth Healthcare
RECRUITING

Melbourne, Victoria, 3002, Australia
Hopital Lyon Sud
NOT_YET_RECRUITING

Lyon, Pierre-Benite, 69310, France
Hopital Saint Louis
NOT_YET_RECRUITING

Paris, Île-de-France Region, 75010, France
IRCCS Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi
RECRUITING

Bologna, Bologna, 40138, Italy
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele)
RECRUITING

Milan, Milano, 20132, Italy
Linear Clinical Research
RECRUITING

Nedlands, Western Australia, 6009, Australia
Rochester Skin Lymphoma Medical Group. PLLC
RECRUITING

Rochester, New York, 14642, United States
Universita degli Studi Di Brescia-Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
RECRUITING

Brescia, Brescia, 25123, Italy
University of California Irvine
RECRUITING

Irvine, California, 92697, United States
Virginia Commonwealth University Massey Comprehensive Cancer Cente
RECRUITING

Richmond, Virginia, 980037, United States
Westmead Hospital
RECRUITING

Westmead, New South Wales, 2145, Australia
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.